ストックスクリーナーアプリを入手
20.84
2.62%
2.865
前日終値:
$17.97
開ける：
$20.6
24時間の取引高:
1,942
Relative Volume:
66.00
時価総額：
$N/A
収益：
-
当期純損益:
-
株価収益率:
33.60
EPS:
0.62
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+2.67%
6か月 パフォーマンス:
+137.32%
1年 パフォーマンス:
+6.04%
1日の値動き範囲:
$20.59
$20.73
1週間の範囲:
$20.59
$20.73
52週間の値動き範囲:
$20.59
$20.73
Defiance Trillion Dollar Club Index Etf Stock (TRIL) Company Profile
TRIL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRIL
Defiance Trillion Dollar Club Index Etf
|
20.73 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
337.45 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
685.64 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
689.01 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
257.69 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
630.51 | 124.43B | 0 | 0 | 0 | 0.00 |
Defiance Trillion Dollar Club Index Etf Stock (TRIL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-11-17 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-04-14 | 開始されました | The Benchmark Company | Buy |
| 2020-10-12 | 開始されました | Evercore ISI | Outperform |
| 2020-09-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-08-17 | 開始されました | Craig Hallum | Buy |
| 2020-06-19 | 開始されました | Oppenheimer | Outperform |
| 2020-05-26 | 開始されました | JMP Securities | Mkt Outperform |
| 2018-04-13 | 再開されました | Leerink Partners | Mkt Perform |
| 2017-07-17 | 開始されました | H.C. Wainwright | Buy |
| 2016-08-03 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-05-15 | 開始されました | Oppenheimer | Outperform |
| 2015-04-27 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Defiance Trillion Dollar Club Index Etf (TRIL) 最新ニュース
TRIL ETF Holdings List — BOATS:TRIL - TradingView
Defiance floats ETF tied to firms, digital assets valued above US$1 trillion - Structured Retail Products
TRIL Stock Fund Price and Chart — BOATS:TRIL - TradingView
US ETF launches from 25th September to 2nd October, 2025 - ETF Express
‘$1 Trillion Club’ ETF Offers Investors Exposure to Tech Giants and Bitcoin - The Currency analytics
A new "Trillion Dollar" ETF based on stocks and Bitcoin has appeared in the US. - Happy Coin News
'$1T Club' ETF offers exposure to tech giants and Bitcoin - Bitget
Tron Inc. Shares Tumble 85% From June Peak Amid DAT Market Slump - Decrypt
Defiance ETFs Launches New Trillion-Dollar Assets ETF: U.S. Access to Tech Giants and Crypto-Linked Plays - Blockchain News
SEC No-Action Letter Creates Opening for More Firms to Serve as Crypto Custodians - Decrypt
Ripple CTO David Schwartz to Step Back, Remain on Board as CTO Emeritus - Decrypt
'$1 Trillion Club' ETF Gives Investors Exposure to Tech Giants—And Bitcoin - Decrypt
Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New “Magnificent 7” of Global Markets - GlobeNewswire
TRIL ETF Analysis: Dividends, Returns NASDAQ:TRIL - TradingView
Defiance Launches JEDI – Drone & Modern Warfare ETF: Exposure to Leading Drone and Modern Warfare Companies - GlobeNewswire
Defiance ETFs Launches QLDY, the First ETF to Pay Distributions Twice Weekly * - GlobeNewswire
Defiance’s QTUM – Quantum Computing ETFSurpasses $2 - GlobeNewswire
Sezary Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | 4SC AG, Seagen Inc., Merck Sharp & Dohme Corp., Innate Pharma, Trillium Therapeutics, Sec - Barchart.com
Defiance ETFs Launches Leveraged + Income ETFs for AMD (AMDU) and Super Micro Computer (SMCC) - GlobeNewswire
Defiance ETFs Launches Leveraged + Income ETFs for Palantir - GlobeNewswire
Defiance Launches VIXI: Enhanced Long Volatility ETF with Leveraged Short S&P 500 Exposure - GlobeNewswire
How Many Trillium Therapeutics Inc. (TSE:TRIL) Shares Do Institutions Own? - ca.sports.yahoo.com
Relapsing Refractory Multiple Myeloma Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape - Barchart.com
Relapsing Refractory Multiple Myeloma Pipeline Outlook Report 2025: Key 55+ Companies And Breakthrough Therapies Shaping The Future Landscape - Menafn
Defiance Launches AIPO: The First ETF Focused on AI Power Infrastructure - GlobeNewswire
Weekly ETF Industry Recap: U.S., Europe, and Canada Highlights – July 7-July 11, 2025 - Trackinsight
Pfizer ends Phase 1b/2 trial for final Trillium CD47 drug - Endpoints News
Defiance ETFs Unveils $MST: The First Leveraged MicroStrategy ETF that Seeks to Pay Income Weekly - GlobeNewswire
PD-1 and PD-L1 Inhibitors Market Report- Expansive Coverage on the Profit Sources - openPR.com
CD47 Targeting Therapeutics Market Robust Expansion is expected to 2034 - openPR.com
Defiance Launches $GLDY, Gold Enhanced Options Income ETF - GlobeNewswire
Defiance’s XMAG ETF Outshines S&P 500 Amid “Magnificent 7” - GlobeNewswire
Defiance ETFs' QTUM, Quantum Computing ETF, Earns 5-Star Morningstar Rating and Surpasses $1 Billion in AUM - GlobeNewswire
CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight - GlobeNewswire
$QTUM, Defiance Quantum Computing ETF, Surpasses $1 Billion in AUM - GlobeNewswire
Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics - Reuters
Zentalis Pharmaceuticals Announces Executive Leadership - GlobeNewswire
Defiance Launches XMAG The First ETF Offering Exposure to the S&P 500 Excluding the “Magnificent 7” Tech Giants - GlobeNewswire
As a Billionaire Activist Takes a Stake, Is Now the Time to Buy Pfizer Stock? - The Globe and Mail
Defiance ETFs Announces Monthly Distributions on $QQQY - GlobeNewswire
Quell Therapeutics Appoints Experienced Biopharma Leader - GlobeNewswire
Genexine, EPD Biotherapeutics to merge for new protein degraders - BioWorld MedTech
Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline - Business Wire
Pension plans still AWOL as Canadian life-sciences venture capital firms re-up for latest funds - The Globe and Mail
Global Breast Cancer Drug Market for Growth, Projected to Reach USD 12,012.1 Million by 2033 at a 1.1% of CAGR - marketresearchblog.org
Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting - Bayer
Defiance Trillion Dollar Club Index ETF (NASDAQ: TRIL)Share Price - intelligentinvestor.com.au
AstraZeneca buys Hamilton-based smart cancer drug maker Fusion Pharmaceuticals for $2-billion - The Globe and Mail
Chronic Myeloid Leukemia Treatment Market On A Growth - GlobeNewswire
Pfizer to acquire Trillium in $2.3bn deal - BioProcess International
Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment - PR Newswire
Defiance Trillion Dollar Club Index Etf (TRIL) 財務データ
Defiance Trillion Dollar Club Index Etf (TRIL) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.50%
0.39%
大文字化:
|
ボリューム (24 時間):